History

Glutathione was identified over a century ago as a ubiquitous cellular thiol and is one of the most-studied molecules in redox biology. Its modern consumer profile splits in two: oral supplementation, long doubted because GSH was thought to be degraded in the gut, gained a credible human footing after the Richie et al. randomized trial (Eur J Nutr, 2015) showed oral dosing could raise body stores; and a much larger, less-evidenced market for intravenous "skin-whitening" and "detox" drips, especially across parts of Asia, which prompted regulatory warnings from the U.S. FDA (2019) and the Philippine FDA (Advisory 2019-182).

Glutathione (GSH) is the body’s main intracellular antioxidant — a small peptide your cells make themselves. It has more genuine human data behind it than most “biohacking” compounds, but that data is mixed and mostly small and short. The one finding that holds up reliably is that oral glutathione can raise the body’s glutathione stores. The things it is actually sold for — IV skin lightening, anti-aging, “detox,” recovery, and performance — are not established in humans, and the injectable cosmetic market is where the documented harm lives. This profile separates the real biochemistry from the marketing.

What it is

Glutathione is an endogenous tripeptide (gamma-L-glutamyl-L-cysteinyl-glycine) synthesized in essentially all human cells in two ATP-dependent steps. Because cysteine availability is normally the rate-limiting factor, N-acetylcysteine (NAC) — a cysteine donor — is the more pharmacologically established way to raise GSH.

It is a true peptide (three amino acids), not a hormone, SARM, or steroid. Its established roles:

Principal intracellular antioxidant and redox buffer. The reactive thiol (-SH) on its cysteine directly scavenges reactive oxygen and nitrogen species.
Enzyme substrate. It is the substrate for glutathione peroxidases (reducing peroxides) and glutathione-S-transferases (conjugating xenobiotics and electrophiles for phase II detoxification). It also recycles vitamins C and E and maintains protein thiols via the GSH/GSSG redox couple.
Pigment chemistry. In melanocytes, glutathione inhibits tyrosinase (partly by interfering with the enzyme’s copper-binding sites) and binds dopaquinone, shifting melanin synthesis from darker eumelanin toward lighter pheomelanin. This is the biochemical rationale behind cosmetic “skin-lightening” claims — but a plausible mechanism is not the same as a proven clinical effect.

The claims

Online and in clinics, glutathione is marketed for skin lightening / “glow” (the dominant real-world use, usually as IV drips or injections), anti-aging, “detox” and liver support, immune support, and athletic recovery and performance. Most of these — especially the anti-aging, detox, recovery, and performance claims — are extrapolated from GSH’s known biochemistry and from cell and animal work, not from robust human outcome trials.

What the evidence actually shows

Oral bioavailability — the historical sticking point. GSH was long assumed to be largely degraded in the gut. The best human RCT (Richie et al., 2015, n=54, 6 months) showed oral glutathione (250 or 1,000 mg/day) did raise body GSH stores — roughly 30–35% in erythrocytes, plasma, and lymphocytes, and ~260% in buccal cells at the high dose — with effects largely reversing after a one-month washout. However, another RCT (Allen & Bradley, 2011, n=40, 4 weeks**)** found no significant change in oxidative-stress biomarkers or GSH status. So oral efficacy is plausible but inconsistent; newer liposomal/micellar formulations are early and small.
Parkinson’s disease — the most-studied serious indication, and instructive. An early open-label IV study (Sechi 1996, n=9) reported ~42% disability improvement, but uncontrolled studies are hypothesis-generating only. A randomized, double-blind, placebo-controlled IV pilot (Hauser 2009, ~20 evaluable) was well tolerated but found no significant difference versus placebo. Intranasal delivery does measurably reach the brain (Mischley 2016, ~269% rise in brain GSH on MRS) — so delivery works — but the strongest result, a randomized placebo-controlled Phase IIb intranasal trial (Mischley 2017, NCT02424708), was negative: not superior to placebo at 3 months. The best Parkinson’s evidence is a null.
Fatty liver (NAFLD). An open-label, single-arm pilot (Honda 2017, ~29 completers, 4 months oral GSH) significantly reduced ALT (68.9 to 58.1 IU/L, p=0.014). Promising but uncontrolled; it needs a randomized trial.
Skin lightening — the weakest base relative to how it’s marketed. The few injectable studies are small, short, and low-quality, and report transient effects with notable adverse-event rates. One IV RCT cited in a 2025 narrative review reported lighter skin in 37.5% versus 18.7% on placebo, but with a 32% adverse-event rate including a case of anaphylaxis, and benefit fading by 6 months. Regulators (Philippine FDA) note there are no published clinical trials of injectable glutathione for skin lightening and no published dosing guidelines. Any benefit appears to reverse on stopping.
General antioxidant / longevity / recovery / performance. Largely extrapolated from cell and animal work and from GSH’s biochemistry — not from robust human outcome trials. Treat this marketing as thin/unproven in humans.

Net: solid human support for “oral GSH can raise body glutathione stores,” and reasonable tolerability in the trials done. But raising a biomarker is not the same as a proven clinical or cosmetic benefit, and the most rigorous disease trial (Parkinson’s) was null.

Legal and regulatory status

FDA (US): Glutathione is not an FDA-approved drug for any wellness, cosmetic, or anti-aging use. Oral and topical forms are sold as dietary supplements or cosmetic ingredients; injectable/IV glutathione used in clinics is compounded, not an approved finished product. The FDA has explicitly warned compounders not to use the dietary-ingredient form of glutathione to make sterile injectables, citing quality and endotoxin concerns. The 2019 action centered on L-glutathione powder labeled “Caution: Dietary Supplement” (supplied to ~100 compounders in 30 states; FDA testing found bacterial endotoxin up to ~5x the limit), with seven documented patient adverse events ranging from nausea/vomiting to dyspnea, one requiring hospitalization. There is no FDA-approved injectable glutathione for skin lightening.
International: The Philippine FDA — a major IV “skin-whitening drip” market — issued Advisory No. 2019-182 against unsafe use of glutathione as a skin-lightening agent, flagging possible liver, kidney, thyroid, and nervous-system toxicity, kidney failure, and Stevens-Johnson syndrome, plus infection risk from non-sterile drips. (In the Philippines, injectable GSH is approved only as an adjunct in cisplatin chemotherapy — not for cosmetic use.)
Controlled-substance status: Glutathione is not a DEA-scheduled controlled substance.
Anti-doping (WADA): Glutathione itself is not on the 2026 WADA Prohibited List — it is not a listed substance in any class. The real anti-doping issue is the route and volume: IV infusions/injections of more than 100 mL per 12-hour period are prohibited under WADA Section M2, “Chemical and Physical Manipulation” (specifically M2.2, a Specified Method) — except for legitimate hospital treatment, surgery, clinical diagnostic investigations, or with a TUE. So a large-volume “glutathione drip” can be a violation because of the infusion method/volume, independent of the substance.

Safety

Oral GSH: Generally well tolerated in trials at studied doses over weeks to months, with no serious safety signals in the RCTs above. Long-term safety data are limited.
Intranasal GSH: Tolerated in Parkinson’s trials.
IV/injectable GSH — the highest-risk use, and where documented harm lives:
- Endotoxin-related reactions (nausea/vomiting progressing to dyspnea and hospitalization) from poorly controlled compounded product — the basis of the FDA action and a published case series.
- Severe allergic / anaphylactoid reactions — a case of anaphylaxis was documented in an IV skin-lightening RCT.
- Regulatory-flagged risks from high-dose cosmetic drips, including Stevens-Johnson syndrome and possible hepatic, renal, thyroid, and neurologic effects.
- Infection transmission from non-sterile administration. Sterility, dosing, and product quality are unregulated in this setting.

The molecule itself is low-toxicity and endogenous. The danger is the unregulated injectable/IV cosmetic market — contamination, allergic reactions, no quality control — not glutathione per se. Repeated high-dose IV use for cosmetic whitening is specifically cautioned against by the FDA and dermatology bodies.

Bottom line

Glutathione is a real, endogenous antioxidant peptide with more human data than most biohacking compounds — but the data is mixed and mostly small and short. The reliable finding is that oral glutathione can raise body glutathione stores; that’s real, but it isn’t proof of the anti-aging, detox, recovery, performance, or skin-lightening benefits it’s sold for. The most rigorous disease trial (intranasal GSH in Parkinson’s) was null, and the skin-lightening evidence is weak, transient, and dominated by an injectable market that regulators have warned about. The peptide is low-toxicity; the IV cosmetic drip is the risky part.

Evidence grade: Preliminary human.